HD 003

Drug Profile

HD 003

Alternative Names: 5-Hydroxy-1-methylhydantoin; HD-003; NZ-419

Latest Information Update: 08 Apr 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Nippon Zoki
  • Developer Hyundai Pharmaceutical; Nippon Zoki
  • Class Hydantoins; Small molecules; Urologics
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal failure

Most Recent Events

  • 05 Oct 2012 Discontinued - Phase-II for Renal failure in Japan (PO)
  • 26 Apr 2007 Phase II development is ongoing
  • 05 Sep 2000 Phase-II clinical trials for Renal failure in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top